In exchange for US$50 M in common stock, NPS Pharmaceuticals has regained full global rights to two orphan drugs from Takeda Pharmaceutical. As Gattex®, teduglutide was launched in the US in February 2013 for adult short bowel syndrome and it is also approved in Europe under the trade name Revestive®. PTH 1-84 (recombinant human parathyroid hormone 1-84) is sold as Preotact® in the EU for post-menopausal osteoporosis and it is being developed in the US as Natpara® for hypoparathyroidism. Takeda obtained commercial rights to the two drugs in certain markets outside of the US with its 2011 acquisition of Nycomed.